Tarsus Pharmaceuticals
TARS
162 hedge funds and large institutions have $1.43B invested in Tarsus Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 58 increasing their positions, 42 reducing their positions, and 25 closing their positions.
12,880% more call options, than puts
Call options by funds: $17.5M | Put options by funds: $135K
100% more funds holding in top 10
Funds holding in top 10: 4 → 8 (+4)
56% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 25
38% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 42
31% more capital invested
Capital invested by funds: $1.09B → $1.43B (+$338M)
9% more funds holding
Funds holding: 148 → 162 (+14)
8.01% more ownership
Funds ownership: 106.05% → 114.07% (+8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$19.6M |
| 2 |
BlackRock
New York
|
+$13.7M |
| 3 |
JP Morgan Chase
New York
|
+$11.8M |
| 4 |
Morgan Stanley
New York
|
+$9.1M |
| 5 |
ABG
Ally Bridge Group
New York
|
+$9.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
-$15.4M |
| 2 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
-$9.91M |
| 3 |
TCM
TCG Crossover Management
Palo Alto,
California
|
-$9.12M |
| 4 |
N
Nuveen
Charlotte,
North Carolina
|
-$6.87M |
| 5 |
IHAM
Integral Health Asset Management
New York
|
-$6.04M |
TARS Hedge Fund Activity: Q3 2024 in Review
162 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Tarsus Pharmaceuticals (TARS) for Q3 2024, worth a combined $1.43B — up 31% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new TARS positions and 25 closed out — a net gain of 14 holders — while 58 added to existing stakes and 42 trimmed.
The largest buyer was Jennison Associates, adding an estimated $19.6M. The largest seller was Vivo Capital, exiting entirely with an estimated $15.4M sold.
- 162 institutional investors held Tarsus Pharmaceuticals (TARS) as of Q3 2024, up from 148 in Q2 2024.
- Funds reported $1.43B of Tarsus Pharmaceuticals stock for Q3 2024, up 31% quarter-over-quarter.
- 39 funds opened new Tarsus Pharmaceuticals positions in Q3 2024 and 25 closed out, a net change of +14 holders.
- The largest Tarsus Pharmaceuticals buyer in Q3 2024 was Jennison Associates, an estimated $19.6M added.
- The largest Tarsus Pharmaceuticals seller in Q3 2024 was Vivo Capital, an estimated $15.4M sold.
Based on aggregated 13F filings for Q3 2024.